JPH07505773A - 標的化されたウイルスベクターを用いた遺伝子治療 - Google Patents

標的化されたウイルスベクターを用いた遺伝子治療

Info

Publication number
JPH07505773A
JPH07505773A JP5517626A JP51762693A JPH07505773A JP H07505773 A JPH07505773 A JP H07505773A JP 5517626 A JP5517626 A JP 5517626A JP 51762693 A JP51762693 A JP 51762693A JP H07505773 A JPH07505773 A JP H07505773A
Authority
JP
Japan
Prior art keywords
virus
envelope
protein
gene
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5517626A
Other languages
English (en)
Japanese (ja)
Inventor
ヤング　アレキサンダー　ティー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPH07505773A publication Critical patent/JPH07505773A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP5517626A 1992-04-03 1993-03-31 標的化されたウイルスベクターを用いた遺伝子治療 Pending JPH07505773A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86279592A 1992-04-03 1992-04-03
US862,795 1992-04-03
US4074893A 1993-03-29 1993-03-29
US040,748 1993-03-29
PCT/US1993/002957 WO1993020221A1 (fr) 1992-04-03 1993-03-31 Therapie genique utilisant des vecteurs viraux cibles

Publications (1)

Publication Number Publication Date
JPH07505773A true JPH07505773A (ja) 1995-06-29

Family

ID=26717389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5517626A Pending JPH07505773A (ja) 1992-04-03 1993-03-31 標的化されたウイルスベクターを用いた遺伝子治療

Country Status (5)

Country Link
EP (1) EP0633943A4 (fr)
JP (1) JPH07505773A (fr)
AU (1) AU3940293A (fr)
CA (1) CA2133411A1 (fr)
WO (1) WO1993020221A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011207913A (ja) * 2002-07-18 2011-10-20 Helix Biopharma Corp 癌細胞増殖を阻害するためのウレアーゼの使用
JP2022519734A (ja) * 2019-02-08 2022-03-24 クリスタル バイオテック インコーポレイテッド Ｃｆｔｒポリペプチドを送達するための組成物及び方法

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643756A (en) * 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
AU689755B2 (en) * 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
ATE263252T1 (de) * 1992-11-09 2004-04-15 Us Health Erzielbare vektorenpartikel
WO1995031566A1 (fr) * 1994-05-13 1995-11-23 Chiron Viagene, Inc. Compositions et procedes de ciblage de vecteurs d'apport de genes
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
WO1997024453A1 (fr) * 1995-12-28 1997-07-10 Chiron Corporation Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6140305A (en) 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
WO1998021228A1 (fr) 1996-11-15 1998-05-22 Canji, Inc. Expression specifique tissulaire de la proteine du retinoblastome
US6074850A (en) * 1996-11-15 2000-06-13 Canji, Inc. Retinoblastoma fusion polypeptides
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
AU737727B2 (en) 1997-04-10 2001-08-30 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
AU766675B2 (en) 1998-03-30 2003-10-23 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
DE19904800C1 (de) * 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
EP2357192A1 (fr) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
AU5011400A (en) 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in t cells
ATE364689T1 (de) 1999-11-18 2007-07-15 Dendreon Corp Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
DK1250453T3 (da) 1999-12-10 2008-08-11 Invitrogen Corp Anvendelse af multiple rekombinations-sites med unik specificitet i rekombinationskloning
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
DE60143798D1 (de) 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
EP1195161A3 (fr) 2000-08-30 2002-07-24 Pfizer Products Inc. Anti-IgE vaccins
EP2412384A1 (fr) 2000-11-28 2012-02-01 MedImmune, LLC Procédés d'administration/dosage d'anticorps anti-rsv pour la prophylaxie et le traitement
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
EP1379637A4 (fr) 2001-03-27 2005-04-06 Dendreon Corp Molecules d'acide nucleique codant une serine protease transmembranaire 9, polypeptides codes et procedes fondes sur ces derniers
WO2002083704A1 (fr) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Facteur de croissance 2, endothelial, vasculaire
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
JP4309758B2 (ja) 2001-05-25 2009-08-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
WO2003002746A2 (fr) 2001-06-29 2003-01-09 Novartis Ag Methode de criblage de perv et son utilisation
EP2014674B1 (fr) 2001-11-26 2014-02-12 Laboratoire Biodim Interactions de protéines/protéines dans un virus d'immunodépression humaine
EP2270049A3 (fr) 2002-04-12 2011-03-09 Medimmune, Inc. Anticorps anti-interleukine-9 recombinants
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
EP1636248A4 (fr) 2002-12-16 2006-09-06 Halozyme Inc Glycoproteine de chondroitinase (chasegp) humaine, son procede de preparation et compositions pharmaceutiques comprenant ladite glycoproteine
EP2368578A1 (fr) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
JP2006518997A (ja) 2003-01-21 2006-08-24 ブリストル−マイヤーズ　スクイブ　カンパニー 新規アシルコエンザイムａ：モノアシルグリセロールアシルトランスフェラーゼ−３（ｍｇａｔ３）をコードするポリヌクレオチドおよびその用途
WO2004071462A2 (fr) 2003-02-12 2004-08-26 Johns Hopkins University Procede et composition pour le traitement d'infections virales utilisant l'interaction tsg101-vps28
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1613273B1 (fr) 2003-04-11 2012-06-13 MedImmune, LLC Anticorps il-9 recombinants et leurs utilisations
EP2302040A1 (fr) 2003-06-13 2011-03-30 University Of Medicine And Dentistry Of New Jersey Utilisation d'ARNm interférase en médecine
CA2532250A1 (fr) 2003-07-15 2005-02-03 Barros Research Institute Antigene eimeria tenella utilise dans l'immunotherapie de la coccidiose
EP1668111A4 (fr) 2003-08-08 2008-07-02 Genenews Inc Biomarqueurs d'osteoarthrite et leurs utilisations
EP1660186B1 (fr) 2003-08-18 2013-12-25 MedImmune, LLC Humanisation d'anticorps
CA2540529C (fr) 2003-10-03 2012-03-13 Vib Vzw Moyens et procedes de recrutement et d'identification de celles souches
US20050227251A1 (en) 2003-10-23 2005-10-13 Robert Darnell Method of purifying RNA binding protein-RNA complexes
ES2687645T3 (es) 2003-10-27 2018-10-26 Merck Sharp & Dohme Corp. Método de diseño de ARNip para el silenciamiento de genes
DK2805728T3 (da) 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
CN101426489A (zh) 2004-04-16 2009-05-06 曹义海 抑制血管生成的成分和方法
AU2005245815B2 (en) 2004-05-07 2011-06-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
US8415298B2 (en) 2004-06-21 2013-04-09 The Board Of Trustees Of The Leland Stanford Junior University Of Stanford Administration of FGF2 for treamtent of anxiety
WO2006007539A1 (fr) * 2004-07-01 2006-01-19 Virxsys Corporation Lignee cellulaire d'encapsidation de vecteurs
JP2008507540A (ja) 2004-07-21 2008-03-13 チューレン ユニバーシティ ヘルス サイエンス センター Ｐａｃａｐ化合物を用いる腎臓機能障害及び多発性骨髄腫の治療
EP2422811A2 (fr) 2004-10-27 2012-02-29 MedImmune, LLC Modulation d'une spécificité d'anticorps par adaptation sur mesure de son affinité a une antigène apparente
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
NZ556158A (en) 2004-12-22 2010-04-30 Auckland Uniservices Ltd Trefoil factors and methods of treating proliferation disorders using same
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
EP1869192B1 (fr) 2005-03-18 2016-01-20 MedImmune, LLC Rearrangement de l'infrastructure d'anticorps
EP3479844B1 (fr) 2005-04-15 2023-11-22 MacroGenics, Inc. Dianticorps covalents et leurs utilisations
CA2618681C (fr) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification et ingenierie d'anticorps presentant des zones de variants fc et procedes d'utilisation de ces anticorps
AU2006304883A1 (en) 2005-10-21 2007-04-26 Genenews Inc. Method and apparatus for correlating levels of biomarker products with disease
HUE026423T2 (en) 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
DK2564864T3 (en) 2005-11-12 2015-04-07 Trustees Of The Leland Board Of FGF-2 related methods for the diagnosis and treatment of depression
RU2462246C2 (ru) 2006-03-30 2012-09-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней
PT2029173T (pt) 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
EP2074225B1 (fr) 2006-10-10 2014-12-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Altérations de l'expression du gène erg spécifiques au cancer de la prostate, et procédés de détection et de traitement en fonction de ces altérations
EP2407548A1 (fr) 2006-10-16 2012-01-18 MedImmune, LLC Molécules ayant des demi-vies réduites, compositions et leurs utilisations
US7964708B2 (en) 2006-11-15 2011-06-21 Limin Li Anti-TSG101 antibodies and their uses for treatment of viral infections
NZ577274A (en) 2006-12-18 2012-10-26 Genentech Inc Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
ES2702087T3 (es) 2007-06-21 2019-02-27 Macrogenics Inc Diacuerpos covalentes y sus usos
US20110206673A1 (en) 2007-06-27 2011-08-25 Liu Dongxu Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
ES2672769T3 (es) 2007-08-29 2018-06-18 Sanofi Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
PL2247304T3 (pl) 2008-04-02 2017-01-31 Macrogenics, Inc. Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
WO2010033279A2 (fr) 2008-06-04 2010-03-25 Macrogenics, Inc. <sb>anticorps à liaison alteree à fcrn et leurs procedes d'utilisation</sb>
CN102282172B (zh) 2008-09-07 2014-02-19 台湾醣联生技医药股份有限公司 抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途
SG172254A1 (en) 2008-12-19 2011-07-28 Macrogenics Inc Covalent diabodies and uses thereof
WO2010072684A1 (fr) 2008-12-22 2010-07-01 Universität Regensburg Utilisation de la protéine norrin dans le traitement de maladies associées à une augmentation de l'activité de tgf-bêta
WO2010124365A1 (fr) 2009-04-27 2010-11-04 Ottawa Hospital Research Institute Compositions et méthodes permettant de moduler les cellules souches et leurs utilisations
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
ES2553440T3 (es) 2009-08-13 2015-12-09 Crucell Holland B.V. Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
WO2011035205A2 (fr) 2009-09-18 2011-03-24 Calmune Corporation Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation
EP2488186B1 (fr) 2009-10-16 2017-05-24 National University of Singapore Utilisations antinéoplasiques d'antagonistes d'artémine
EP2496245B1 (fr) 2009-11-02 2016-07-20 The Administrators Of The Tulane Analogues de polypeptide d'activation d'adénylate cyclase hypophysaire (pacap) et procédés pour leur utilisation
EP2496604B1 (fr) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Anticorps contre cd20 canine
DK2536747T3 (en) 2010-02-19 2017-12-04 Université de Liège POLYNUCLEOTIDE USED FOR THE TREATMENT OF INFLUENZA A VIRUS-INDUCED DISEASES AND CODING MODIFIED MX PROTEIN, THE MODIFIED MODIFIED MX PROTEIN, AND A TRANSGENT ANIMATED DRIVE, AS AN EXTENDED ANIMALS, AS AN EXTERNAL DRIVE, AS AN EXTENDED ANIMALS
TWI627964B (zh) 2010-07-09 2018-07-01 傑森疫苗防護公司 抗-人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
WO2012013249A1 (fr) 2010-07-30 2012-02-02 Université de Liège Protéine 1 de la matrice dentinaire (dmp1) pour l'utilisation dans des compositions pharmaceutiques
CA2807127C (fr) 2010-08-02 2019-02-12 Leslie S. Johnson Di-anticorps covalents et utilisations associees
WO2012094511A2 (fr) 2011-01-05 2012-07-12 Rhode Island Hospital Compositions et procédés destinés au traitement de lésion ou de maladie orthopédique
WO2012162068A2 (fr) 2011-05-21 2012-11-29 Macrogenics, Inc. Domaines de liaison du sérum déimmunisé et leur utilisation pour prolonger la demi-vie du sérum
WO2013040309A2 (fr) 2011-09-16 2013-03-21 Fate Therapeutics, Inc. Compositions wnt et utilisations thérapeutiques desdites compositions
ES2690305T3 (es) 2011-09-16 2018-11-20 Ottawa Hospital Research Institute Composiciones de Wnt7a y métodos de utilización de las mismas
LT2814844T (lt) 2012-02-15 2017-10-25 Novo Nordisk A/S Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
LT2814842T (lt) 2012-02-15 2018-11-12 Novo Nordisk A/S Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9944685B2 (en) 2012-07-02 2018-04-17 Medizinische Universität Wien Complement split product C4d for the treatment of inflammatory conditions
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014120975A1 (fr) 2013-02-01 2014-08-07 California Institute Of Technology Immunocontraception à médiation par un anticorps
WO2015127351A1 (fr) 2014-02-24 2015-08-27 Celgene Corporation Méthodes d'utilisation d'un activateur du céréblon pour l'expansion de cellules neurales et le traitement de troubles du système nerveux central
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
US10966414B2 (en) 2015-05-26 2021-04-06 California Institute Of Technology Population control using engineered translocations
US10729790B2 (en) 2015-05-26 2020-08-04 Salk Institute For Biological Studies Motor neuron-specific expression vectors
US9920100B2 (en) 2015-06-05 2018-03-20 The Chinese University Of Hong Kong Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
WO2017182981A1 (fr) 2016-04-20 2017-10-26 Washington University Agoniste de ppar ou agoniste de lxr à utiliser pour traiter le lupus érythémateux systémique par modulation de l'activité lap
AU2017261804A1 (en) 2016-05-12 2018-11-29 Adicet Therapeutics, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
AU2018370120C1 (en) 2017-11-15 2024-05-30 Adicet Therapeutics, Inc. Methods for selective expansion of d3 yd T-cell populations and compositions thereof
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
TWI790370B (zh) 2018-04-02 2023-01-21 美商必治妥美雅史谷比公司 抗trem-1抗體及其用途
US11965172B2 (en) 2018-11-05 2024-04-23 California Institute Of Technology DNA sequence modification-based gene drive
US11325978B2 (en) 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
EP3890757A1 (fr) 2018-12-03 2021-10-13 Adicet Bio Inc. Méthodes d'expansion sélective in vivo de populations de lymphocytes t gamma delta et compositions associées
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
EP4084819A1 (fr) 2020-01-03 2022-11-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Tnap administrée localement pour favoriser la santé parondontale
IL295891A (en) 2020-02-24 2022-10-01 Immatics Us Inc Methods for propagating t cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
WO2022147029A2 (fr) 2020-12-31 2022-07-07 Immatics US, Inc. Polypeptides cd8, compositions et leurs méthodes d'utilisation
WO2022157548A1 (fr) 2021-01-24 2022-07-28 Forrest Michael David Inhibiteurs d'utilisations cosmétiques et thérapeutiques d'atp synthase
IL308337A (en) 2021-05-13 2024-01-01 Us Health Preparations and methods for the treatment of sickle cell disease
CA3226402A1 (fr) 2021-07-19 2023-01-26 Dounia ABBADI Compositions de vecteurs viraux adeno-associes et methodes de promotion de la regeneration musculaire
WO2023064255A2 (fr) 2021-10-15 2023-04-20 The Regents Of The University Of California Diagnostic et traitement de la thrombocytopénie induite par anti-pf4
WO2023081167A2 (fr) 2021-11-02 2023-05-11 The Regents Of The University Of California Mutants de p-sélectine et modulation de signalisation médiée par intégrine
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
US20250092106A1 (en) 2022-01-25 2025-03-20 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2023200897A1 (fr) 2022-04-13 2023-10-19 The Regents Of The University Of California Utilisation d'il-6 virale dans le traitement du cancer
EP4514821A1 (fr) 2022-04-28 2025-03-05 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
AU2023262596A1 (en) 2022-04-28 2024-12-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514834A1 (fr) 2022-04-28 2025-03-05 Immatics US, Inc. Polypeptides récepteurs de tgfbêta négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
WO2023215825A1 (fr) 2022-05-05 2023-11-09 Immatics US, Inc. Procédés d'amélioration de l'efficacité d'un lymphocyte t
WO2024013727A1 (fr) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Matériau et procédés d'appariement amélioré par génie biologique de régions variables de liaison à l'antigène
WO2025096649A1 (fr) 2023-11-01 2025-05-08 Immatics US, Inc. Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504361A (ja) * 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
EP0487587A1 (fr) * 1989-08-18 1992-06-03 Chiron Corporation Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
CA2092195C (fr) * 1990-09-21 2000-04-18 Douglas J. Jolly Lignee cellulaire a encapsidation retrovirale
ATE188740T1 (de) * 1991-02-19 2000-01-15 Univ California Viruspartikel mit veraendertem wirtspektrum
WO1993000103A1 (fr) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Proteines d'enveloppe chimeriques pour le ciblage de virus
AU2512792A (en) * 1991-08-30 1993-04-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Defective interfering hiv particles with chimeric cd4-env
WO1993014188A1 (fr) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011207913A (ja) * 2002-07-18 2011-10-20 Helix Biopharma Corp 癌細胞増殖を阻害するためのウレアーゼの使用
JP2022519734A (ja) * 2019-02-08 2022-03-24 クリスタル バイオテック インコーポレイテッド Ｃｆｔｒポリペプチドを送達するための組成物及び方法
JP2025013873A (ja) * 2019-02-08 2025-01-28 クリスタル バイオテック インコーポレイテッド Ｃｆｔｒポリペプチドを送達するための組成物及び方法
US12522636B2 (en) 2019-02-08 2026-01-13 Krystal Biotech, Inc. Compositions and methods for delivering CFTR polypeptides

Also Published As

Publication number Publication date
AU3940293A (en) 1993-11-08
WO1993020221A1 (fr) 1993-10-14
EP0633943A4 (fr) 1997-05-02
EP0633943A1 (fr) 1995-01-18
CA2133411A1 (fr) 1993-10-14

Similar Documents

Publication Publication Date Title
JPH07505773A (ja) 標的化されたウイルスベクターを用いた遺伝子治療
Boeckle et al. Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems
JP2773833B2 (ja) 感染性薬剤の供給系
CN1646154B (zh) 与白蛋白融合的抗-血管生成肽
EP0259212B1 (fr) Expression d&#39;un antigène spécifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement préventif ou curatif de la tumeur correspondante
JPH08504091A (ja) 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス
US6534051B1 (en) Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
HU230364B1 (hu) Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
JPH09509329A (ja) 遺伝子搬送媒体を標的とする組成物及び方法
EA003832B1 (ru) Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования
Martin et al. Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope
JPH10500852A (ja) 遺伝子治療のための安全なベクター
JPH10506001A (ja) 核酸複合体を高等真核生物の細胞に導入するための組成物
JP2000508893A (ja) プラスモウイルス由来の新規ワクチン
JP2003530360A (ja) 薬剤送達のためのペプチド複合体
Moon et al. Current status of experimental therapeutics for prostate cancer
JPH10501403A (ja) 抗体−エンベロープ融合タンパク質および野生型エンベロープ融合タンパク質を含むレトロウィルスベクターを用いる細胞型特異的遺伝子移入
Vile et al. Strategies for achieving multiple layers of selectivity in gene therapy
DE69527544T2 (de) Kombinationsvektoren zum austragen von genmaterial
Anwer et al. Targeted gene delivery: a two-pronged approach
DE69534633T2 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
EP1308167A1 (fr) Vésicles présentatrices d&#39;antigène
JPH08501453A (ja) 外来遺伝子を送達し、発現させるベクター
EP1491216A1 (fr) Medicaments comprenant des nanoparticules proteiques creuses et substance therapeutique destinee a etre a transferee dans des cellules avec lesquelles elles se fondent
US20120258540A1 (en) Methods for modifying virus surfaces

Legal Events

Date Code Title Description
A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20040720

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20050222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20051004